EUVIMEDEUVIMED entdecken
Crossref

MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics

Huang Chen, Yiying Liu, Feihang Wang, Jin Sun, Chengxiang Gong, Min Zhu, Minjie Xu, Qiye He, Rui Liu, Zhixi Su iD, Dingrong Zhong iD, Lingxiao Liu iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Huang Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China. Hauptthemen laut MEDLINE: Thyroid Nodule, DNA Methylation, Thyroid Neoplasms, Thyroid Cancer, Papillary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Accurately distinguishing between benign thyroid nodules (BTNs) and papillary thyroid cancers (PTCs) with current conventional methods poses a significant challenge.

Objective

We identify DNA methylation markers of immune response–related genes for distinguishing BTNs and PTCs.

Methods

In this study, we analyzed a public reduced representative bisulfite sequencing dataset and revealed distinct methylation patterns associated with immune signals in PTCs and BTNs. Based on these findings, we developed a diagnostic classifier named the Methylation-based Immune Response Signature (MeIS), which was composed of 15 DNA methylation markers associated with immune response–related genes. We validated MeIS's performance in 2 independent cohorts: Z.S.'s retrospective cohort (50 PTC and 18 BTN surgery-leftover samples) and Z.S.'s preoperative cohort (31 PTC and 30 BTN fine-needle aspiration samples).

Results

The MeIS classifier demonstrated significant clinical promise, achieving areas under the curve of 0.96, 0.98, 0.89, and 0.90 in the training set, validation set, Z.S.'s retrospective cohort, and Z.S.'s preoperative cohort, respectively. For the cytologically indeterminate thyroid nodules, in Z.S.'s retrospective cohort, MeIS exhibited a sensitivity of 91% and a specificity of 82%; in Z.S.'s preoperative cohort, MeIS achieved a sensitivity of 84% and a specificity of 74%. Additionally, combining MeIS and BRAF V600E detection improved the detecting performance of cytologically indeterminate thyroid nodules, yielding sensitivities of 98% and 87%, and specificities of 82% and 74% in Z.S.'s retrospective cohort and Z.S.'s preoperative cohort, respectively.

Conclusion

The 15 markers we identified can be employed to improve the diagnostic of cytologically indeterminate thyroid nodules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleDNA MethylationThyroid NeoplasmsThyroid Cancer, PapillaryHumansMaleFemaleRetrospective StudiesMiddle AgedAdultDiagnosis, DifferentialBiomarkers, TumorBiopsy, Fine-NeedleAged

Stichwörter der Autor:innen

DNA methylationimmune response signaturesneutrophil activationthyroid nodule diagnostics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
  • R&D Department, Singlera Genomics (Shanghai) Ltd., Shanghai 201203, China.
  • Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, Shanghai 200030, China.
  • Shanghai Institute of Medical Imaging, Fudan University, Shanghai 200032, China.

ORCID-Profile: Zhixi Su, Dingrong Zhong, Lingxiao Liu

Förderung

  • National High Level Hospital Clinical Research Funding
  • National Key Research and Development Program of China

Zitieren

APA

Chen, H., Liu, Y., Wang, F., Sun, J., Gong, C., Zhu, M., Xu, M., He, Q., Liu, R., Su, Z., Zhong, D., & Liu, L. (2024). MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae141

Vancouver

Chen H, Liu Y, Wang F, Sun J, Gong C, Zhu M, et al. MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae141

BibTeX
@article{Chen2024,
  author = {Chen, Huang and Liu, Yiying and Wang, Feihang and Sun, Jin and Gong, Chengxiang and Zhu, Min and Xu, Minjie and He, Qiye and Liu, Rui and Su, Zhixi and Zhong, Dingrong and Liu, Lingxiao},
  title = {MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae141}
}
Kostenlos starten →